Chronic Corticosteroid Use Is Associated with Higher Perioperative Morbidity After Elective Primary Total Hip

Assil Mahamid1,2, Hamza Murad1,2, Miri Elgabsi3

  • 1Department of Orthopedics, Hasharon Hospital, Rabin Medical Center, Tel Aviv University, Tel Aviv 6997801, Israel.

Insights

Chronic corticosteroid use increases risks for patients undergoing elective total hip arthroplasty (THA). Steroid users face higher rates of complications, major bleeding, and in-hospital mortality, highlighting a need for increased clinical recognition of this perioperative risk.

Area of Science:

  • Orthopedic Surgery
  • Pharmacology
  • Health Services Research

Background:

  • Chronic corticosteroid use is prevalent for autoimmune and inflammatory conditions.
  • The perioperative risks associated with chronic steroid use in elective total hip arthroplasty (THA) are not fully understood.

Purpose of the Study:

  • To evaluate the association between chronic corticosteroid use and postoperative complications and hospital outcomes after elective primary THA.

Main Methods:

  • Retrospective cohort study using the National Inpatient Sample (2016-2021).
  • Identified adult patients undergoing elective primary THA.
  • Defined chronic corticosteroid use by ICD-10-CM code Z79.52.
  • Utilized multivariable logistic regression and propensity score matching (PSM).

Main Results:

  • Chronic corticosteroid use (0.91% of cohort) was linked to higher comorbidity burden.
  • Associated with increased odds of any postoperative complication (OR 1.32), major bleeding (OR 1.46), prolonged hospitalization (OR 1.26), and in-hospital mortality (OR 2.53).
  • Matched cohort analysis confirmed significant association with overall complications (OR 1.84) and acute kidney injury (OR 2.10).

Conclusions:

  • Chronic corticosteroid use is an independent predictor of increased perioperative morbidity after elective THA.
  • Highlights chronic steroid use as a marker for increased perioperative risk.
  • Suggests the need for greater clinical recognition and informs future perioperative management strategies.

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
Cushing Syndrome II: Pathophysiology01:19

Cushing Syndrome II: Pathophysiology

Cortisol production is normally governed by the hypothalamic–pituitary–adrenal (HPA) axis, which maintains hormonal balance through tightly regulated feedback mechanisms. Disruption of this regulatory system is central to the development of Cushing syndrome, whether the excess cortisol originates from external medications or internal pathology. Persistent cortisol elevation alters metabolism, immune function, and endocrine signaling, producing the characteristic clinical features of the...
Cushing Syndrome I: Introduction01:26

Cushing Syndrome I: Introduction

Cushing syndrome refers to the collection of clinical manifestations that arise when tissues are exposed to excessive amounts of cortisol or cortisol-like medications over an extended period. Cortisol, a glucocorticoid produced by the adrenal cortex, regulates metabolism, immune responses, and the body’s adaptation to stress. When its concentration remains chronically elevated, these physiological pathways become dysregulated, resulting in the characteristic features of the syndrome.Exogenous...
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids01:25

Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids

Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
COPD: Management Using Bronchodilators and Corticosteroids01:26

COPD: Management Using Bronchodilators and Corticosteroids

Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...